Fulgent Genetics Inc (FLGT) USD0.0001

Sell:$18.30Buy:$20.79$0.13 (0.68%)

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$18.30
Buy:$20.79
Change:$0.13 (0.68%)
Market closed | Prices delayed by at least 15 minutes
Sell:$18.30
Buy:$20.79
Change:$0.13 (0.68%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Key people

Ming Hsieh
Chairman of the Board, Chief Executive Officer
Jian Xie
President, Chief Operating Officer
Paul Kim
Chief Financial Officer
Hanlin Gao
Chief Scientific Officer, Laboratory Director
Regina E. Groves
Independent Director
Linda Marsh
Independent Director
Michael Nohaile
Independent Director
Click to see more

Key facts

  • EPIC
    FLGT
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Healthcare Facilities
  • ISIN
    US3596641098
  • Market cap
    $583.36m
  • Employees
    1,313
  • Shares in issue
    33.64m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.